On February 27, 2026, XTL Biopharmaceuticals Ltd. received a notice from Nasdaq indicating that it may be delisted due to being perceived as a 'public shell'. The company plans to appeal this decision to a Nasdaq Hearings Panel, which will postpone the delisting until a ruling is made.